What is the revenue and EPS growth rate for Milestone Scientific year over year?

Did Milestone Scientific beat or miss consensus estimates last quarter?

What is Milestone Scientific's gross profit margin?

What is Milestone Scientific's latest dividend and current dividend yield?

What guidance did Milestone Scientific's management provide for the next earnings period?

What factors drove the changes in Milestone Scientific's revenue and profit?

What does Milestone Scientific do and what are its main business segments?

What were the key takeaways from Milestone Scientific's earnings call?

- **Revenue Surge**: 25% YoY growth to $2.3M, fueled by 100%+ gains in medical and international sales.
- **Strategic Shift**: Direct-to-consumer dental model boosts margins, while medical focuses on 3-5 key clinics for reimbursement validation.
- **Key Hires**: New sales leader and Board member to accelerate medical adoption and federal partnerships.
- **Cash Position**: $1.3M cash, solid liquidity for growth initiatives.
- **Risks**: Lumpy international sales and slow medical adoption, but strong product performance in clinical use.

**【CEO Summary Section】**
- **Revenue Growth**: Q2 revenue increased 25% YoY to $2.3 million, driven by a 100% surge in international dental sales and a 267% rise in medical revenue.
- **Dental Segment Strategy**: Shifted to direct-to-consumer e-commerce model, reducing distribution costs and improving margins. U.S. dental sales were flat but expected to grow with targeted marketing.
- **Medical Segment Progress**: Secured Medicare Part B reimbursement in New Jersey, Texas, and Florida. Early adoption by pain management clinics, with 5-10 active users.
- **Leadership Expansion**: Hired Jason Papes as Global Head of Sales and Marketing, and added Shanth Thiyagalingam to the Board for reimbursement expertise.
- **Focus Areas**: Accelerate CompuFlo Epidural adoption in pain management clinics, expand international dental sales, and pursue VA/DoD partnerships.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: Dental ($2.0M, +25%), Medical ($32K, +133%), International ($1.0M, +103%).
- **Gross Profit**: $1.6M (69% margin), up 15% YoY.
- **Expenses**: SG&A $3.0M (+3.4%), R&D $52K (-85%).
- **Liquidity**: $1.3M cash, $3.9M working capital, no debt.

**【Q&A Highlights】**
- **Medical Adoption Strategy**: Focus on 3-5 key clinics to collect reimbursement data, then scale. Targeted federal partnerships (VA/DoD) for faster adoption.
- **International Growth**: 48% of revenue from international, driven by new distributors and direct shipments from China to avoid tariffs.
- **VA Progress**: Engaged with Shamrock to pilot CompuFlo in eastern VA facilities, with favorable pricing terms.
- **Brazil Update**: On hold due to U.S.-Brazil trade tensions, but long-term potential remains.
- **Product Performance**: No reported wet taps or short taps in clinical use, validating STA and CompuFlo reliability.

Milestone Scientific (MLSS)-15 Aug 25-2025 Q2 Earnings call transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

MLSS

MLSS fundamentals

You can ask Aime